See today's BioWorld Asia
To read the full story, subscribe or sign in.

EMA validates two filings for Daiichi-Astrazeneca’s ADC

March 5, 2024
By Marian (YoonJee) Chu
The EMA validated two marketing approval applications of Daiichi Sankyo Co. Ltd. and Astrazeneca plc’s antibody-drug conjugate (ADC) datopotamab deruxtecan (dato-dxd) on Mar. 4, for two types of lung and breast cancer.
BioWorld Asia Regulatory Cancer Oncology Antibody-drug conjugate Europe Japan BLA EMA FDA Phase III